{"organizations": [], "uuid": "5224a343ddd499cac539f35d8300073c8d2b846a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-vandas-hetlioz-demonstrates-effica/brief-vandas-hetlioz-demonstrates-efficacy-to-treat-jet-lag-disorder-idUSFWN1QN0EO", "country": "US", "domain_rank": 408, "title": "BRIEF-Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.631, "site_type": "news", "published": "2018-03-05T20:12:00.000+02:00", "replies_count": 0, "uuid": "5224a343ddd499cac539f35d8300073c8d2b846a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-vandas-hetlioz-demonstrates-effica/brief-vandas-hetlioz-demonstrates-efficacy-to-treat-jet-lag-disorder-idUSFWN1QN0EO", "ord_in_thread": 0, "title": "BRIEF-Vanda's Hetlioz Demonstrates Efficacy To Treat Jet Lag Disorder", "locations": [], "entities": {"persons": [{"name": "hetlioz", "sentiment": "none"}], "locations": [], "organizations": [{"name": "vanda pharmaceuticals inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Vanda Pharmaceuticals Inc:\n* HETLIOZ® (TASIMELTEON) DEMONSTRATES EFFICACY TO TREAT JET LAG DISORDER IN AN 8 HOUR PHASE ADVANCE CLINICAL STUDY\n* VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATED SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFITS IN NIGHTTIME AND DAYTIME SYMPTOMS OF JET LAG DISORDER​\n* VANDA PHARMACEUTICALS - ‍RESULTS FROM JET8 STUDY SHOWED CLINICALLY MEANINGFUL EFFECTS OF HETLIOZ 20 MG ON PRIMARY ENDPOINT,MULTIPLE SECONDARY ENDPOINTS​\n* VANDA PHARMACEUTICALS INC - ‍INTENDS TO SEEK MARKETING APPROVAL FOR USE OF HETLIOZ IN TREATMENT OF JET LAG DISORDER​\n* VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATES IMPROVEMENT IN TOTAL SLEEP TIME BY 85 MINUTES VERSUS PLACEBO IN STUDY​\n* VANDA PHARMACEUTICALS INC - ‍HETLIOZ DEMONSTRATES IMPROVEMENT IN NEXT DAY ALERTNESS VERSUS PLACEBO IN STUDY​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T20:12:00.000+02:00", "crawled": "2018-03-06T22:28:59.015+02:00", "highlightTitle": ""}